Answers are grounded in this paper and cite their sources.
Molecular networking reveals pyridine-fused compounds that inhibit HIV-1 replication, suggesting a new therapeutic approach.
With the employment of feature-based molecular networking-guided screening of a refined reference library, four unconventional conjugates, pyricitristerols A-D (1-4), pyridine-fused C₂₅ abeo-steroids featuring a novel 6/7/7/6/5-fused framework, were isolated from a plant-sourced fungus Penicillium citrinum YSC-1. To account for the pyridine moiety, a biosynthetical route was proposed and substantiated by a concise four-step biomimetic semisynthesis from readily prepared precursors 5-8, highlighted by a defining gold-catalyzed one-pot condensation that forged the core architecture. Biological evaluation revealed that 1-4 potently inhibit HIV-1 replication (IC₅₀ = 0.9-3.6 μM), and structure-activity analysis showed that the pyridine moiety served as the core pharmacophore, while C-23/C-24 stereochemistry finely tuned activity. Mechanistic investigations integrating time-of-addition/washout assays and molecular docking simulations demonstrated these compounds as early stage HIV-1 entry inhibitors that target host-cell surface components, potentially including receptors, such as CCR5, with the pyridine core and C-23 hydroxy group directly engaging in specific binding interactions.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: